GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Revenue per Share

Nuformix (LSE:NFX) Revenue per Share : £0.00 (TTM As of Sep. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Nuformix Revenue per Share?

Nuformix's revenue per share for the six months ended in Sep. 2022 was £0.00. Nuformix's revenue per share for the trailing twelve months (TTM) ended in Sep. 2022 was £0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Nuformix's Revenue per Share or its related term are showing as below:

LSE:NFX's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Nuformix Revenue per Share Historical Data

The historical data trend for Nuformix's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Revenue per Share Chart

Nuformix Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Revenue per Share
Get a 7-Day Free Trial - - - - -

Nuformix Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuformix's Revenue per Share

For the Biotechnology subindustry, Nuformix's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuformix's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's PS Ratio distribution charts can be found below:

* The bar in red indicates where Nuformix's PS Ratio falls into.



Nuformix Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Nuformix's Revenue Per Share for the fiscal year that ended in Mar. 2022 is calculated as

Revenue Per Share (A: Mar. 2022 )=Revenue (A: Mar. 2022 )/Shares Outstanding (Diluted Average) (A: Mar. 2022 )
=0.05/598.448
=0.00

Nuformix's Revenue Per Share for the quarter that ended in Sep. 2022 is calculated as

Revenue Per Share (Q: Sep. 2022 )=Revenue (Q: Sep. 2022 )/Shares Outstanding (Diluted Average) (Q: Sep. 2022 )
=0/707.261
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuformix  (LSE:NFX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Nuformix Revenue per Share Related Terms

Thank you for viewing the detailed overview of Nuformix's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuformix (LSE:NFX) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.

Nuformix (LSE:NFX) Headlines

From GuruFocus

5 Oil & Gas Companies To Consider This Year

By InvestmentUnderground InvestmentUnderground 03-25-2012

Baron Funds Comments on Newfield Exploration

By Holly LaFon Holly LaFon 03-16-2017

Newfield Exploration Company (NFX) EVP and COO Gary D Packer sells 23,000 Shares

By GuruFocus Research GuruFocus Editor 03-11-2010